Subtopic Deep Dive
Patent Foramen Ovale and Migraine with Aura
Research Guide
What is Patent Foramen Ovale and Migraine with Aura?
Patent Foramen Ovale (PFO) and Migraine with Aura examines the epidemiological link between right-to-left shunting via PFO and migraine attacks triggered by microemboli in patients with aura.
PFO prevalence is higher in migraineurs with aura than controls, with closure showing mixed efficacy in sham-controlled trials (Dowson et al., 2008; Schwedt et al., 2008). Over 10 key papers, including 2 NEJM trials, document stroke risk and migraine reduction post-closure (Mas et al., 2001; Mas et al., 2017). Observational data report migraine improvement in 80% of cases after percutaneous closure (Schwerzmann et al., 2004).
Why It Matters
PFO closure reduces refractory migraine frequency in aura patients unresponsive to drugs, as shown in MIST trial where STARFlex device yielded 50% responder rate despite lacking statistical significance versus sham (Dowson et al., 2008). In cryptogenic stroke cohorts with PFO, closure plus antiplatelets cut recurrence by 75% over antiplatelets alone (Mas et al., 2017). Guidelines recommend PFO evaluation in young stroke patients with migraine aura (Goldstein et al., 2014). Divers with large PFO face 5-fold decompression illness risk (Torti et al., 2004).
Key Research Challenges
Proving Causal Microembolism
Distinguishing microemboli from vasospasm in migraine aura remains unresolved, as imaging fails to consistently detect shunts during attacks (Lamy et al., 2002). Observational closure benefits lack sham controls in most studies (Schwerzmann et al., 2004). MIST trial showed no significant difference versus sham despite 80% observational response (Dowson et al., 2008).
Standardizing Closure Efficacy
Sham-controlled trials like MIST report non-significant migraine reduction post-PFO closure (Dowson et al., 2008). Patient selection criteria vary, complicating meta-analyses (Schwedt et al., 2008). Long-term recurrence data exceed 10% in high-risk PFO subgroups (Mas et al., 2001).
Risk Stratifying Divers
PFO size correlates with decompression illness odds, but absolute risk stays low at 5 events per 10,000 dives (Torti et al., 2004). Screening protocols absent standardized echo criteria across populations. Co-morbid migraine aura elevates undetected risk in divers (Schwerzmann et al., 2004).
Essential Papers
Guidelines for the Primary Prevention of Stroke
Larry B. Goldstein, Cheryl Bushnell, Robert J. Adams et al. · 2014 · Stroke · 2.6K citations
The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of stroke among individuals who have not previously experienced a stroke or...
Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or Both
Jean‐Louis Mas, Caroline Arquizan, Catherine Lamy et al. · 2001 · New England Journal of Medicine · 1.4K citations
Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin...
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
Jean‐Louis Mas, Geneviève Dérumeaux, B. Guillon et al. · 2017 · New England Journal of Medicine · 1.1K citations
Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those as...
Migraine Intervention With STARFlex Technology (MIST) Trial
Andrew Dowson, Michael Mullen, Richard Peatfield et al. · 2008 · Circulation · 583 citations
Background— Patent foramen ovale (PFO) is prevalent in patients with migraine with aura. Observational studies show that PFO closure resulted in migraine cessation or improvement in ≈80% of such pa...
Clinical and Imaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale
Catherine Lamy, C. Giannesini, Mathieu Zuber et al. · 2002 · Stroke · 505 citations
Background and Purpose — Patent foramen ovale (PFO) has been identified as a potential risk factor for stroke, but the mechanisms of PFO-associated stroke remain unsettled. The aim of our study was...
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
Christian Pristipino, Horst Sievert, Fabrizio D’Ascenzo et al. · 2018 · European Heart Journal · 416 citations
Abstract The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have...
Stroke recurrence in patients with patent foramen ovale
Julien Bogousslavsky, S. Garazi, Xavier Jeanrenaud et al. · 1996 · Neurology · 415 citations
Patent foramen ovale (PFO) is more common in patients with stroke than in matched controls, but the stroke mechanism and late prognosis are not well known. We studied features, coexisting causes, a...
Reading Guide
Foundational Papers
Start with Mas et al. (2001, NEJM, 1353 citations) for PFO-stroke recurrence risk, then Dowson et al. (2008, MIST trial) for migraine closure data, and Goldstein et al. (2014) guidelines for prevention context.
Recent Advances
Prioritize Mas et al. (2017, NEJM, 1108 citations) on closure vs. antiplatelets post-stroke, Pristipino et al. (2018) position paper on PFO management.
Core Methods
Transesophageal/bubble echo detects shunts; sham-controlled RCTs assess closure; systematic reviews meta-analyze prevalence and response rates (Schwedt et al., 2008).
How PapersFlow Helps You Research Patent Foramen Ovale and Migraine with Aura
Discover & Search
Research Agent uses searchPapers('PFO migraine aura closure trial') to retrieve 10+ core papers like Dowson et al. (2008) MIST trial, then citationGraph reveals Mas et al. (2001) as upstream stroke reference with 1353 citations, and findSimilarPapers expands to Torti et al. (2004) for diving risks.
Analyze & Verify
Analysis Agent applies readPaperContent on Dowson et al. (2008) to extract 50% responder rates, verifyResponse with CoVe cross-checks against Mas et al. (2017) for closure efficacy consistency, and runPythonAnalysis performs meta-analysis of GRADE-graded evidence from 5 trials using pandas for odds ratios on migraine reduction.
Synthesize & Write
Synthesis Agent detects gaps in sham-control data post-MIST via contradiction flagging across Schwedt et al. (2008) review, while Writing Agent uses latexEditText to draft trial comparison tables, latexSyncCitations for 10-paper bibliography, and latexCompile for publication-ready review; exportMermaid visualizes PFO-stroke-migraine pathway graph.
Use Cases
"Meta-analyze migraine reduction rates from PFO closure trials with Python."
Research Agent → searchPapers('PFO closure migraine RCT') → Analysis Agent → readPaperContent(Dowson 2008, Mas 2017) → runPythonAnalysis(pandas meta-analysis of responder rates, GRADE scoring) → CSV export of forest plot data.
"Write LaTeX review on PFO migraine stroke links citing NEJM trials."
Research Agent → citationGraph(Mas 2001) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF) → peer review simulation.
"Find code for PFO shunt size analysis from echo imaging papers."
Research Agent → exaSearch('PFO size migraine echo quantification') → Code Discovery → paperExtractUrls(Torti 2004) → paperFindGithubRepo → githubRepoInspect(echo analysis Jupyter notebook) → runPythonAnalysis(sandbox test on sample data).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PFO-migraine papers via searchPapers → citationGraph → GRADE grading, outputting structured report on closure efficacy. DeepScan applies 7-step CoVe chain to verify microembolism claims in Lamy et al. (2002) against MIST data. Theorizer generates hypotheses linking PFO size (Torti et al., 2004) to aura severity from 10 core papers.
Frequently Asked Questions
What defines the PFO-migraine with aura association?
PFO enables right-to-left shunting of microemboli, triggering cortical aura in migraineurs; prevalence doubles versus controls (Schwedt et al., 2008).
What methods test PFO closure for migraine?
Percutaneous closure with STARFlex or Amplatzer devices in sham RCTs like MIST; transesophageal echo confirms shunt pre/post (Dowson et al., 2008).
What are key papers on PFO migraine?
MIST trial (Dowson et al., 2008, 583 citations) tests closure; Schwedt systematic review (2008, 268 citations) quantifies prevalence; Schwerzmann (2004, 265 citations) reports attack reduction.
What open problems persist?
Causality unproven in sham trials; optimal patient selection unclear; long-term migraine recurrence post-closure exceeds 10% in subgroups (Mas et al., 2001).
Research Cardiovascular and Diving-Related Complications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Patent Foramen Ovale and Migraine with Aura with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers